HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors
HONG KONG, June 21, 2021 /PRNewswire/ -- HUTCHMED (China) Limited ("HUTCHMED
Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021
SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
Hutchison China MediTech to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on June 10, 2016
HONG KONG, June 6, 2016 /PRNewswire/ -- Hutchison China MediTech (LONDON STOCK EXCHANGE: HCM, NASDAQ: HCM) based inChina, and globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products, today announced that Chief Execu...
